FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/31/2025
Back to search
Official data from USPTO
RIBOCURE PHARMACEUTICALS AB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
04/03/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
12/29/2023
Registration date
04/01/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/01/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
64
Owner location
SE
Examiner
KEAN, AMY C
Law office
N30
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized wording "Ribocure" in black with the tittle over the letter "i" in orange and the letter "o" being formed by two curved vertical curves with the left curve in orange and the right curve in black, all over the stylized wording "Pharmaceuticals AB" in black, with all of the foregoing to the right of a stylized caduceus formed by a staff with a ball on top with one curving bar in black and a smaller waving ribbon over the bar in orange.
Holders and representatives
Holders
Ribocure Pharmaceuticals AB
Representatives
Zhi Dong HSML, P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
medicines for humans for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; biological preparations for medical purposes for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; chemical preparations for pharmaceutical purposes for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; chemical preparations for medical purposes for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; drugs for medical purposespharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; medicinal preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating metabolic disorders; anticoagulants; cardiovascular pharmaceutical preparations; pharmaceutical preparations for ocular or intraocular surgery; depuratives for the body; veterinary preparations for the treatment and diagnosis of gastrointestinal diseasescardiovascular diseasesmetabolic diseasesliver diseases; pesticides; medical dressings; composite materials for dental purposes; diapers for pets
Class 42
technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research services; pharmaceutical research and development services; scientific research; chemical research and analysis; development and test of chemical production methods; biochemical research and analysis; development of pharmaceutical preparations and medicines; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design
Publications
History of USPTO decisions and trademark events.
26 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/14/2025
FIMP
FINAL DISPOSITION PROCESSED
10/14/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
08/01/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/14/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
07/14/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/01/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/01/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
04/01/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/11/2025
PUBO
PUBLISHED FOR OPPOSITION
02/11/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/05/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/18/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/10/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/10/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/10/2025
RFNT
REFUSAL PROCESSED BY IB
09/08/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/16/2024
RFRR
REFUSAL PROCESSED BY MPU
08/16/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/08/2024
CNRT
NON-FINAL ACTION WRITTEN
08/07/2024
DOCK
ASSIGNED TO EXAMINER
07/28/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/13/2024
MAFR
APPLICATION FILING RECEIPT MAILED
02/27/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/21/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/15/2024
Continuous trademark protection
Get notified about every new filing that threatens RIBOCURE PHARMACEUTICALS AB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.